Lab to Startup Naresh Sunkara PhD

Shahram Seyedin-Noor is the founder and managing partner at Civilization Ventures. Shahram received a JD from Harvard and worked at Wilson Solsinis and Cooley before going into investment banking at firms like Goldman Sachs and Bank of America. He then entered the startup world co-founding several startups. He eventually ended up Angel investing and in 2017, launched Civilization Ventures, focused on supporting cutting-edge innovations in health tech and biology.

Shahram has over a dozen exits under his belt, which is a phenomenal achievement. Here are some of his investments: Rewrite (acq. by Intellia), Replace (acq. by Tome), Lemonaid (acq. by 23andme), Singular Bio (acq. by Invitae), Rocket Pharma (listed on Nasdaq), Palamedrix (acq. by SomaLogic), Foresight Diagnostics, BillionToOne, Omada and others. Shahram takes an active role in company building. Prior to founding CV, Shahram was the founding CEO/Chairman of Inspirna, an oncology therapeutics company currently in Phase 2 human trials, and the CFO and VP of Corporate Development at NextBio, a genomics software pioneer acquired by Illumina.

Shownotes:
https://www.civilizationventures.com/ Success has a thousand fathers but failure is an orphan Accountability: Few people blame themselves for failure and give credit for success to others Evolution of mindset: Don’t let others dictate what you can or supposed to do in life EQ is more/equally important than IQ Transition from law school to startups Advice for recruiting a non-scientific co-founder Rewrite therapeutics acquired by Intellia Investment thesis at Civilization Ventures: Drive to do things differently Lessons learned from exits Contact email: shahram@civilizationventures.com

Leo Polovets is the Co-founder and General Partner at Susa Ventures. Leo focuses on enterprise software and technical products at Susa. About two years ago, He also started Humba Ventures, a fund that invests in deep tech and critical national sectors like energy and defense at Humba.  

Leo led Susa's investments in Mashgin, People Data Labs, Scalyr, and Treasury Prime. Having been a software engineer for 10+ years, Leo approaches challenges with an engineering mindset and supports portfolio companies in vetting and hiring technical talent. Prior to Susa, Leo was the second engineering hire at Linkedin, where he worked on the first versions of products like LinkedIn Jobs and LinkedIn Groups. Leo then worked on payment fraud detection algorithms at Google, and was also an early engineer at Factual, where he built data processing software. Leo received a bachelor's degree in Engineering and Applied Science (Computer Science) from Caltech.

We talk about lessons that translate from investing in traditional startups; explore lessons learned about market sizing, pricing, team dynamics, managing burn, scaling, valuation and many other topics in the deep tech space.

 
Shownotes: https://humbaventures.com/ Leo’s presentation on “Exploring Startup Ideas” https://docs.google.com/presentation/d/1C-JFkqsY40tidqPD1OZbV3-OXPAyrsPIV5Q_00PkToQ/edit#slide=id.g221d008c440_0_35 Thinking about making money for scientific founders Thinking about market attributes for a potential startup Intro to Humba ventures Investing in deep tech Founder-market fit; Time to make money Investment thesis Communication: between team members, to investors and beyond Working with startup teams: Commercialization Pricing in deep tech: Think of value being created How to ask for money for your product? Aloha robot- https://www.youtube.com/watch?v=HaaZ8ss-HP4&t=5s Story telling Manage your burn! Scaling: Calibrating on talent; learning to delegate; firing Bs and B+s on the team Keeping up with new technologies Thoughts on valuation What Leo likes to hear while being pitched to

Caroline Winnett is the Executive Director of Berkeley Skydeck, a startup accelerator at the University of California, Berkeley. Skydeck started as a mentoring space in 2012 and soon translated into one of the leading startup accelerators in the world.

SkyDeck was Formed as a partnership between UC Berkeley’s Haas School of Business, the College of Engineering, and the Office of the Vice Chancellor for Research. While it offers all the benefits of a traditional accelerator, what makes Skydeck special is the vast resources of the world’s number one ranked public university. The robust and vibrant ecosystem includes a deep network of advisors, industry partners, and attracts some of the best investors. I have seen its evolution first hand because of my own association since my postdocs days at UC Berkeley

We discuss the evolution of the startup ecosystem at UC Berkeley and then dive into how Skydeck has been supporting deep tech startups, challenges and lessons learned.
 
Shownotes:

Berkeley Skydeck: https://skydeck.berkeley.edu/ Startup resources at Berkeley: https://begin.berkeley.edu/ Berkeley named top university for number of venture-backed companies
Evolution of startup ecosystem at UC Berkeley: Pre & post Skydeck Changing academia-industry relations Skydeck is just not for UC Berkeley community Support for deep tech startups at Skydeck Criteria for picking deep tech startups for accelerations Lessons learned from working with scientific and faculty founders Scalability and market potential of deep tech startups Partnerships with corporations: realistic expectations Picking advisors Commercializing deep tech startups Investing in deep tech: Evaluating founders Tips for applying to Berkeley Skydeck Apply here: https://skydeck.berkeley.edu/apply/

Paul Grand is the founder and CEO; Ayelet Marom is the Program Director for BioTools Innovator, which focuses specifically on biotools; and Jim West is the Associate Director, BioTools Innovator, who was previously the Co-Founder and CEO of, Clara Biotech, which was founded in 2018 and was acquired by Innovaprep in the summer of 2023. Jim was the first founder to go through the biotools program.

In this episode of lab to startup, we first discuss some of the challenges that affect medtech and biotool technology startups, and then go into ways that medtech innovator, an accelerator program is helping founders in this space, especially around lessons learned and how the program has evolved into one of the best accelerators in this space.
https://medtechinnovator.org/about-us/ Founding story of Medtech Innovator Things medtech startups struggle with: Articulating value proposition; understanding reimbursement; having the wrong CEO; staying in stealth mode; choosing the wrong indication Medtech innovator “Value program” Value coaches from established companies like J&J How startups get accepted to the program No equity, no fees and no strings attached for being a part of the program Bringing the right investors to the table to support founders Biotools innovator program: https://biotoolsinnovator.org/ Challenges in the biotools space How investors are different in this space Pay for Service as a model Story of Jim West, Founder and CEO of Clara biotech, that went through the program Advice on slide decks Info session videos: https://www.youtube.com/@Medtechinnovatorchannel

Kenichi Nogami is the co-founder and CEO of Metcela, a clinical-stage biotechnology startup pioneering the research and development of fibroblast and stem cell-based therapy for chronic heart diseases that currently have limited therapeutic options.

We talk about the current treatments for heart failure and how the fibroblast technology could help this space. We explore the founding story; setting smaller milestones and fundraising to meet those goals; the role of recruiting firms in hiring in japan; building a flat structure at the startup, as opposed to a hierarchical system that Japan is generally known for; and how Ken’s investment banking experience helped with acquisition of another biotech startup; and many other stories.

Shownotes
https://www.metcela.com/en/ Fibroblast technology for treating Heart failure Current treatments and potential of regenerative capabilities Founding story: Investment banker meets a PhD student and launch a startup Nedo, Japan: Technology-Based Startup Support Program https://www.nedo.go.jp/english/activities/activities_ZZJP_100091.html
IP: University waives its right to file a patent and the startup files the patent Co-founder chemistry Business model evolution Immune response challenges developing cell therapy for heart diseases Fundraising stories: Raising money from Japanese investors vs those outside Japan Raising from university derived VCs Cell manufacturing challenges Acquiring a startup while being a startup Evolution as a CEO Team and hiring process: Supply drove the hiring more than demand in many cases Building culture Hierarchy vs flat structure: decision making process Challenges building a biotech startup in Japan- talent, infrastructure; and need to expand globally

Caleb Bell III, Ph.D., is a venture partner at Corundum Systems Biology and also the President of Corundum convergence institute.

We talk about the founding story of Bell biosystems; how they were able to work at various labs around the country with very little money; building teams, culture; raising money, interacting with investors, leadership transitions; and also how the company filed for bankruptcy, although after he left the startup;. Kalub agreed to dip into his experiences both as a founder and investor, and share some of the lessons learned around all these topics, which I believe will be very helpful for aspiring or current founders out there.

Shownotes:
https://www.linkedin.com/in/caleb3/ Early life as an entrepreneur and grad school training Thoughts on working with law firms: corporate vs IP attorneys Inspiration for launching Bell Biosystems (hint: Listening to NPR science Friday) Labs around the country helped perform the initial proof of concept experiments Market hypothesis Convincing the right kind of people to work with you: challenges and lessons learned Advice on recruiting and growing teams Culture: Two types of sins Becoming a manager from a founder Communicating with investors: Being a good steward of money Magnetic cells Thoughts on charging early customers;price discovery Sophisticated vs unsophisticated investors: Do your research! Leadership transitions Transitioning to investing: PE, VC Lessons learned from time at the PE firm Corundum systems biology https://www.csb.co.jp/